Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine.

Keith L KnutsonMatthew S BlockNadine NortonCourtney L ErskineTimothy J HobdayAllan B DietzDouglas PadleyMichael P GustafsonDanell Puglisi-KnutsonToni Kay MangskauSaranya ChumsriAmylou C DueckLavakumar KaryampudiGlynn WilsonAmy C Degnim

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Degenerate HLA-DR-based HER2 vaccines induce sustainable HER2-specific T cells and antibodies. Future studies, could evaluate whether vaccination during adjuvant treatment with trastuzumab-containing regimens improves patient outcomes.

Keyphrases

early stage
epidermal growth factor receptor
current status
combination therapy
case control
sensitive detection
smoking cessation
breast cancer risk